Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzyme replacement royalties, gene-therapy milestone payments, and orphan-drug pricing updates make BioMarin Pharmaceutical鈥檚 SEC disclosures uniquely complex. Finding the R&D footnotes that explain trial costs or the revenue breakout for therapies like Voxzogo can take hours.
Stock Titan solves that problem. Our AI reads every BioMarin document on EDGAR鈥�10-Ks, 10-Qs, 8-Ks, S-8s, and especially Form 4 insider filings鈥攁nd produces plain-English briefs. Use it for BioMarin SEC filings explained simply or to dive deeper with red-line comparisons and keyword search. Whether you need the latest BioMarin quarterly earnings report 10-Q filing or an older BioMarin annual report 10-K simplified, you鈥檒l get both the full PDF and an AI summary that flags pipeline milestones and revenue drivers.
AG真人官方-time alerts track BioMarin Form 4 insider transactions real-time, giving you instant visibility into executive stock moves. Curious about compensation? The platform links directly to the BioMarin proxy statement executive compensation section, while our explanations spotlight option grants and performance metrics. For sudden developments, the system pushes notifications with BioMarin 8-K material events explained鈥攆rom FDA feedback to collaboration agreements鈥攕o you never miss market-moving news.
Practical use cases include monitoring BioMarin insider trading Form 4 transactions before trial readouts, comparing quarter-over-quarter R&D spend through our BioMarin earnings report filing analysis, and understanding BioMarin SEC documents with AI when assessing long-term cash burn. All filings update the moment they hit EDGAR, giving analysts, portfolio managers, and biotech enthusiasts a single source for accurate, timely disclosure intelligence.
Viking Global and affiliated funds report a 6.4% common-stock stake in BioMarin Pharmaceuticals (BMRN). Collectively the Reporting Persons beneficially own 12,288,611 shares out of 192,001,650 shares outstanding as of June 30, 2025. Ownership is shared (no reported sole voting or dispositive power); the holdings are held across several Viking entities and funds (largest positions reported: Viking Global Investors LP 12,288,611; Viking Global Performance LLC 8,208,825; Viking Global Equities Master Ltd. 8,044,650; Viking Long Fund Master Ltd. 2,856,671; Viking Global Opportunities Liquid Portfolio Sub-Master LP 1,223,115). The filing states the securities were not acquired to change or influence control of the issuer. Signatures on the amendment are dated August 14, 2025.
Primecap Management Co/CA filed an amendment to Schedule 13G reporting beneficial ownership of 15,795,383 shares of BioMarin Pharmaceutical Inc. common stock, equal to 8.24% of the class. The filing shows Primecap has sole voting power over 15,087,400 shares and sole dispositive power over 15,795,383 shares. The statement is for CUSIP 09061G101 and designates the security class as common stock. Item 10 certifies the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing is dated as an event on 06/30/2025 and signed on 08/13/2025.
BioMarin Pharmaceutical Inc. (BMRN) 鈥� Form 4
On 08/01/2025, director Ian T. Clark was awarded 7,000 restricted stock units (RSUs) of BioMarin common stock, recorded with transaction code 鈥淎鈥� (acquisition). Because RSUs are granted by the company, the stated price is $0.00 and no open-market cash outlay occurred. Following the grant, Clark鈥檚 direct beneficial ownership stands at 7,000 shares; no indirect holdings or derivative positions were reported. The filing contains no sales, options, or additional equity instruments.
The transaction represents routine director equity compensation rather than an opportunistic purchase, but it modestly increases insider alignment with shareholders. No earnings data, guidance changes, or other material corporate events accompany this filing.
Filing: Form S-8 filed by BioMarin Pharmaceutical Inc. (BMRN) on August 5, 2025 to register additional shares under an employee plan.
Key action: The registrant amended the BioMarin 2017 Equity Incentive Plan (as amended April 1, 2025) and registered 8,000,000 additional shares of Common Stock for issuance under the 2017 Plan.
Other facts: The statement incorporates by reference prior S-8 filings (File Nos. 333-218695, 333-234231, 333-262824, 333-275273); exhibits include the Restated Certificate of Incorporation, Amended and Restated Bylaws, legal opinion of Cooley LLP, consent of KPMG LLP, the amended 2017 Plan (Exhibit 99.1), and a filing fee table. The filing is signed by executive officers and directors on August 5, 2025.
Q2 2025 highlights: BioMarin (BMRN) generated total revenue of $825.4 million, up 16% YoY, led by VOXZOGO (+20%) and VIMIZIM (+21%). Cost of sales grew in line with volume, while R&D (-12%) and SG&A (-12%) fell, expanding operating income to $276.9 million versus $120.5 million last year. Net income more than doubled to $240.5 million; diluted EPS rose to $1.23 from $0.55.
Margins & cash: Gross margin remained about 81.5%; operating margin widened to 33.5% (19.0% prior year). Operating cash flow climbed 117% to $359.7 million, lifting cash and equivalents to $1.21 billion. Convertible debt is unchanged at $600 million, leaving net leverage very low. Retained earnings swung to a $232 million surplus from a $(195) million deficit at year-end.
Product mix Q2 2025:
- VOXZOGO $221.4 m
- VIMIZIM $215.4 m
- NAGLAZYME $128.9 m
- PALYNZIQ $105.9 m
- ALDURAZYME $56.4 m
- BRINEURA $48.7 m
- KUVAN $27.0 m (generic erosion)
- ROCTAVIAN $9.2 m
Balance-sheet notes: Inventory increased 9% to $1.34 billion; AOCI turned to a $(44.6) million loss mainly from FX hedge marks. Three customers represent 38% of net product revenue.
Events after quarter-end: Closed $270 million all-cash acquisition of Inozyme Pharma, adding late-stage enzyme therapy BMN-401; assessing impact of newly enacted U.S. OBBB tax law.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
